Zobrazeno 1 - 10
of 47
pro vyhledávání: ''
Autor:
Glenn Liu, Patricia LoRusso, Elisabeth I. Heath, Yanwei Zhang, Justine Yang Bruce, Elizabeth A. Sadowski, David R. Shalinsky, Michael A. Tortorici, Aurora Breazna, Anne M. Traynor, Priscila H. Goncalves, Alejandro D. Ricart
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:527-538
PURPOSE: PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity o
Autor:
Sernaz Uzunoglu, Irfan Cicin, Nazım Can Demircan, Osman Kostek, Muhammet Bekir Hacioglu, Bulent Erdogan, Erdem Yilmaz, Nermin Tuncbilek, Ali Gökyer
Publikováno v:
Cancer chemotherapy and pharmacology. 83(4)
To evaluate whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (m
Autor:
Michael Henke, Niels Jorgen Ostergaard Skartved, Pol Specenier, Rainald Knecht, P Pamperin, Thomas Gauler, Ivan D. Horak, Yassine Lalami, M-C Kaminsky, Ulrich Keilholz, J Krauß, Andreas Dietz, S Braun, Jean-Pascal Machiels
Publikováno v:
Cancer chemotherapy and pharmacology
Purpose The purpose of the trial was to assess the efficacy and tolerability of Sym004, a novel 1:1 mixture of two chimeric monoclonal antibodies (992 and 1024) targeting non-overlapping epitopes of the anti-epidermal growth factor receptor (EGFR), i
Autor:
Toshiaki Takahashi, Asuka Tsuya, Kazuto Nishio, Takayuki Yoshino, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Shinya Ueda, Narikazu Boku, Masahiro Fukuoka, Isamu Okamoto, Wataru Okamoto
Publikováno v:
Cancer Chemotherapy and Pharmacology. 72:1063-1071
Nimotuzumab is a humanized IgG₁ monoclonal antibody to the epidermal growth factor receptor (EGFR) and has demonstrated the absence of severe dermatological toxicity commonly caused by other EGFR-targeting antibodies. We conducted a phase I study t
Autor:
Tomohide Tamura, Noboru Yamamoto, Hitoshi Arioka, Tatsu Shimoyama, Yutaka Ueda, Yasuhide Yamada, Haruyasu Murakami
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose TSU-68 is a low molecular weight inhibitor of the tyrosine kinases for vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor β, and fibroblast growth factors receptor 1. In this study, we assessed the recomme
Autor:
de Weger, Vincent A, Goel, Sanjay, von Moos, Roger, Schellens, Jan H M, Mach, Nicholas, Tan, Eugene, Anand, Suraj, Scott, Jeffrey W, Lassen, Ulrik N, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Cancer Chemotherapy and Pharmacology, 81(1), 73. Springer Verlag
Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1–3, FGFR 1–3, and PDGFR. This study was performed to investigate the potential drug–drug interaction of dovitinib with the CYP1A2 inhibitor fluvoxamine in pa
Autor:
Li-Tzong Chen, Yee Chao, Yang Chung Lin, Wen-Chi Chou, Tseng Sheng Yang, Jen-Shi Chen, Kuan Der Lee
Publikováno v:
Cancer Chemotherapy and Pharmacology. 65:151-157
Advanced biliary tract carcinoma (BTC) is a dismal disease with no standard chemotherapy. We investigated efficacy and toxicity of biweekly oxaliplatin with 48-h infusion of 5-FU/LV in advanced BTC.All patients had histologic confirmation of BTC, at
Autor:
Carolyn D. Britten, Amarnath Sharma, Anthony W. Tolcher, Feng Guo, Pamela N. Munster, Karen A. Gelmon, Stephen P. Letrent
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:97-109
CP-724,714 is an orally available, small molecule, potent HER-2 tyrosine kinase inhibitor under development for the treatment of advanced HER2-overexpressing cancers. In this study, the influence of baseline clinical characteristics and pathophysiolo
Autor:
Noboru Yamamoto, Tomohide Tamura, Yasuhito Fujisaka, Yasuhide Yamada, Atsushi Horiike, Haruyasu Murakami, Tatsu Shimoyama
Publikováno v:
Cancer Chemotherapy and Pharmacology. 61:489-496
The objectives of this phase I dose-finding study of erlotinib were to investigate the toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess the pharmacokinetic (PK) profile and antitumor activity in Japanese p
Publikováno v:
Cancer Chemotherapy and Pharmacology. 59:631-636
A phase I study of TCF therapy, which consists of paclitaxel (TXL: Taxol) + cisplatin (CDDP) + 5-fluorouracil (5-FU), in advanced gastric cancer patients was performed to determine the recommended dose (RD) for a phase II study by checking the dose-l